Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?

Nature Clinical Practice Oncology volume 3, pages 178–179 (2006)Cite this article

boxed-textPiccart-Gebhart MJ et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–1672

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Romond EH et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684

    Article  CAS  Google Scholar 

  2. Slamon D et al. (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab and with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer: BCIRG 006 study [abstract #1]. Breast Can Res Treat 94: S5

    Google Scholar 

  3. Seidman AD et al. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215–1221

    Article  CAS  Google Scholar 

  4. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365: 1687–1717

  5. [No authors listed] (2005) Helping the informed patient decide [editorial]. Lancet 365: 2064

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, and Associate Professor at Cornell University Medical College, New York, NY, USA

    Andrew D Seidman

Authors
  1. Andrew D Seidman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew D Seidman.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seidman, A. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?. Nat Rev Clin Oncol 3, 178–179 (2006). https://doi.org/10.1038/ncponc0460

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0460

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing